Table 5.
Comparison in prophylaxis strategy
| No. | First Author Location |
Preventive and Manamegent Strategy | No anticoagulant | |
|---|---|---|---|---|
| Prophylaxis | Therapeutic | |||
| 1 | Klok, Kruip [10] | All patients received at least standard doses thromboprophylaxis. | - | - |
| 2 | Al-Samkari, Karp Leaf [28] | All patients received standard dose thromboprophylaxis. | - | - |
| 3 | Mohamud and Mukhtar [39] | - | Only patients with thromboembolic event administered with therapeutic anticoagulant. | Most patients did not receive any prophylaxis. |
| 4 | Kaptein, Stals [11] | All patients received standard dose thromboprophylaxis | - | - |
| 5 | Gonzalez-Fajardo, Ansuategui [12] |
33 patients (31.13%) were treated with thromboprophylaxis. (Low Molecular Weight Heparin) |
- | Most patients did not receive any prophylaxis. |
| 6 | Munoz-Rivas, Abad-Motos [16] | All patients received standard dose thromboprophylaxis. | Only patients with confirmed TE complications given therapeutic dose. | - |
| 7 | Tholin, Fiskvik [17] | Most patients received thromboprophylaxis (61%). | - | - |
| 8 | Martínez Chamorro, Revilla Ostolaza [18] |
All patients received prophylaxis. (Enoxaparin) |
- | - |
| 9 | Elboushi, Syed [41] |
All patients received prophylaxis. (Low Molecular Weight Heparin) |
- | - |
| 10 | Rali, O’Corragain [29] | All patients received dose of thromboprophylaxis. | - | - |
| 11 | Erben, Franco-Mesa [30] | All patients received standard dose thromboprophylaxis. (Heparin) | - | - |
| 12 |
Filippi, Sartori [31] USA |
Most patients given thromboprophylaxis. (Low Molecular Weight Heparin) |
- | - |
| 13 | Brandao, de Oliveira [32] | Most patients (72%) given thromboprophylaxis. (Low Molecular Weight Heparin) | - | - |
| 14 | Haksteen, Hilderink [20] |
All patients received standard dose thromboprophylaxis. (Nadroparin) |
- | - |
| 15 | Arribalzaga, Martinez-Alfonzo [21] |
Most patients (68.3%) received standard prophylactic dose. (Low Molecular Weight Heparin) |
Intermediate and therapeutic doses of LMWH were used more in ICU patients (18%) than in ward patients (12.6%). | - |
| 16 | Valle, Bonaffini [22] | 91 patients received standard prophylactic dose. | - | - |
| 17 | Silva, Jorge [27] | 29 patients received standard prophylactic dose. | - | - |
| 18 | Whyte, Kelly [42] | All patients given thromboprophylaxis in the absence of contraindication | - | - |
| 19 | Bruggemann, Spaetgens [23] | Most patients (55%) received standard prophylactic dose. | - | - |
| 20 | Chang, Rockman [34] | - | Most patients (62.2%) received therapeutic dose. | - |
| 21 | Chaudhary, Padrnos [35] | Most patients (80.4%) received standard prophylactic dose. | - | - |
| 22 | Fujiwara, Nakajima [38] | Only 10% received standard prophylactic dose. Mostly in ICU (n = 20/35 patients) | - | - |
| 23 | Lodigiani, Iapichino [25] | Thromboprophylaxis was used in 100% of ICU patients and 75% of those on the general ward. | - | - |
| 24 | Vivan, Rigatti [38] |
68% of patients were receiving prophylactic or therapeutic doses. (Heparin) |
- | |
| 25 | Fraissé, Logre [26] | All patients received usual (prophylactic) or full-dose (therapeutic) anticoagulation according to their risk factors for thrombosis | - | |